Análisis del proceso de prescripción de inhibidores PCSK9 en los servicios de cardiología de los hospitales españoles y propuesta de optimización. Estudio IKIGAI
- Barrios, Vivencio
- Escobar, Carlos
- Arrarte, Vicente 1
- Bravo, Marisol
- del Campo, Alfredo 2
- Hidalgo, Rafael 3
- Recasens, Lluís
- Cequier, Ángel 4
- 1 Servicio de Cardiología, Hospital General Universitario de Alicante, Alicante, España
- 2 Sociología y Comunicación, Gabinete de estudios sociosanitarios, Madrid, España
- 3 Servicio de Cardiología, Hospital Universitario Virgen Macarena, Sevilla, España
- 4 Servicio de Cardiología, Hospital Universitario de Bellvitge, Barcelona, España
ISSN: 0214-9168, 1578-1879
Argitalpen urtea: 2021
Alea: 33
Zenbakia: 6
Orrialdeak: 296-305
Mota: Artikulua
Beste argitalpen batzuk: Clínica e investigación en arteriosclerosis
Laburpena
Aims To ascertain the formalities and procedures required for the prescription of PCSK9 inhibitors in the cardiology departments of Spanish hospitals, making proposals for improvement to optimize the prescription process. Methods A first phase of collecting information about the variables and administrative procedures required for the prescription of PCK9 inhibitors and the elaboration of a specific questionnaire and a second phase of collecting data with an online self-administered questionnaire. Results A total of 88 hospitals participated in the study (mean number of beds 625; mean number of cardiologists 18 ± 10; 78% university hospitals). There was underuse of PCSK9 inhibitors (real prescription of 30 treatments/year; potential prescription of 80), mainly because of not fulfilling the therapeutic positioning report (52%) and application refusal (31%). Beyond the requirements of the therapeutic positioning report, 1.2 ± 0.4 applications are required with 8.5 ± 4.2 variables. Only 21% of hospitals did not require a previous authorization process and in the remaining hospitals, approval from a committee was necessary. The accumulated time of the prescription process was 6 weeks. Discontinuation rates during follow-up were 9% ± 12%. Conclusions Treatment with PCSK9 inhibitors is clearly underused in Spain. This is mainly due to both inappropriate identification of patients, and complex administrative procedures that could inhibit/discourage prescription by cardiologists and consequently, limit their use. In addition, there is a substantial delay from drug approval tadministration.